Efficacy and tolerability of peginterferon alpha-2a and peginterferon alpha-2b in Iranian patients with chronic hepatitis C

Hepatitis Monthly

Volumn 15, Issue 9, 2015, Pages

  Pouresmaeeli, Mahdiyar ^a,b   Alavian, Seyed Moayed ^a,b   Keshvari, Maryam ^c   Salimi, Shima ^a,b   Mehrnoush, Leila ^a,b  

^a Baqiyatallah Research Center for Gastroenterology and Liver Disease   (Iran)

^b Middle East Liver Diseases Research Center   (Iran)

^c HIGH INSTITUTE FOR RESEARCH AND EDUCATION IN TRANSFUSION MEDICINE   (Iran)

Author keywords

Hepatitis C; Iran; Peginterferon alfa 2a; Peginterferon alfa 2b

Indexed keywords

ERYTHROPOIETIN; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ALOPECIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLEEDING; CHRONIC HEPATITIS C; COMMON COLD; COUGHING; CROSS-SECTIONAL STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; EARLY VIRAL RESPONSE; FEMALE; FEVER; HEADACHE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; INSOMNIA; IRANIAN PEOPLE; MAJOR CLINICAL STUDY; MALE; MYALGIA; PRURITUS; RAPID VIRAL RESPONSE; RECURRENCE RISK; RETROSPECTIVE STUDY; SKIN DISEASE; SUSTAINED VIRAL RESPONSE; TREATMENT RESPONSE;

EID: 84990309002     PISSN: 1735143X     EISSN: 17353408     Source Type: Journal    
DOI: 10.5812/hepatmon.30780     Document Type: Article

References (24)

1. World Health Organization. Hepatitis C. Available from: http://www.who.int/mediacentre/factsheets/fs164/en/.
2. Merat S, Rezvan H, Nouraie M, Jafari E, Abolghasemi H, Radmard AR, et al. Seroprevalence of hepatitis C virus: the first population-based study from Iran. Int J Infect Dis. 2010;14 Suppl 3:e113–6. doi: 10.1016/j.ijid.2009.11.032. [PubMed: 20362479]
3. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245–64. doi: 10.1016/j.jhep.2011.02.023. [PubMed: 21371579]
4. World Health Organizatin. Guidelines for the screening, Care and Treatment of Persons with Hepatitis C Infection. Available from: http://www.who.int/hiv/pub/hepatitis/hepatitis-c-guidelines/en/.
5. Pearlman BL. Protease inhibitors for the treatment of chronic hepatitis C genotype-1 infection: the new standard of care. Lancet Infect Dis. 2012;12(9):717–28. doi: 10.1016/S1473-3099(12)70060-9. [PubMed: 22647717]
6. Gellad ZF, Reed SD, Muir AJ. Economic evaluation of direct-acting antiviral therapy in chronic hepatitis C. Antivir Ther. 2012;17(6 Pt B):1189–99. doi: 10.3851/IMP2430. [PubMed: 23186646]
7. El Raziky M, Fathalah WF, El-Akel WA, Salama A, Esmat G, Mabrouk M, et al. The Effect of Peginterferon Alpha-2a vs. Peginterferon Alpha-2b in Treatment of Naive Chronic HCV Genotype-4 Patients: A Single Centre Egyptian Study. Hepat Mon. 2013;13(5):e10069. doi: 10.5812/hepatmon.10069. [PubMed: 23922556]
8. Romero-Gomez M, Planas R, Ampuero J, Sola R, Garcia-Samaniego J, Diago M, et al. Meta-analysis: pegylated interferon alpha-2a achieves higher early virological responses than alpha-2b in chronic hepatitis C. Aliment Pharmacol Ther. 2013;37(11):1065–73. doi: 10.1111/apt.12314. [PubMed: 23581537]
9. Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. Pegylated interferon-alpha2a and ribavirin versus pegylated interferon-alpha2b and ribavirin in chronic hepatitis C: a meta-analysis. Drugs. 2013;73(3):263–77. doi: 10.1007/s40265-013-0027-1. [PubMed: 23436591]
10. Alavian SM, Behnava B, Tabatabaei SV. The comparative efficacy and safety of peginterferon alpha-2a vs. 2b for the treatment of chronic HCV infection: a meta-analysis. Hepat Mon. 2010;10(2):121–31. [PubMed: 22312385]
11. Awad T, Thorlund K, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials. Hepatology. 2010;51(4):1176–84. doi: 10.1002/hep.23504. [PubMed: 20187106]
12. Singal AK, Jampana SC, Anand BS. Peginterferon alfa-2a is superior to peginterferon alfa-2b in the treatment of naive patients with hepatitis C virus infection: meta-analysis of randomized controlled trials. Dig Dis Sci. 2011;56(8):2221–6. doi: 10.1007/s10620-011-1765-0. [PubMed: 21643737]
13. Dogan UB, Atabay A, Akin MS, Yalaki S. The comparison of the efficacy of pegylated interferon alpha-2a and alpha-2b in chronic hepatitis C patients with genotype 1. EurJ Gastroenterol Hepatol. 2013;25(9):1082–5. doi: 10.1097/MEG.0b013e32836076d1. [PubMed: 23524524]
14. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580–93. doi: 10.1056/NEJMoa0808010. [PubMed: 19625712]
15. Jin YJ, Lee JW, Lee JI, Park SH, Park CK, Kim YS, et al. Multicenter comparison of PEG-IFN alpha2a or alpha2b plus ribavirin for treatment-naive HCV patient in Korean population. BMC Gastroenterol. 2013;13:74. doi: 10.1186/1471-230X-13-74. [PubMed: 23627926]
16. Brochot E, Nguyen-Khac E, Duverlie G. Equal efficacy between the two types of peginterferon on HCV: a matter of relapse? Antiviral Res. 2013;98(1):1–3. doi: 10.1016/j.antiviral.2013.02.006. [PubMed: 23422645]
17. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol. 2009;24(3):336–45. doi: 10.1111/j.1440-1746.2009.05789.x. [PubMed: 19335784] 18.
18. Tanaka H, Tsukuma H, Kasahara A, Hayashi N, Yoshihara H, Masuzawa M, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer. 2000;87(5):741–9. [PubMed: 10925370]
19. JahanbakhshSefidi F, Keyvani H, Monavari SH, Alavian SM, Fakhim S, Bokharaei-Salim F. Distribution of hepatitis C virus genotypes in Iranian chronic infected patients. Hepat Mon. 2013;13(1):e7991. doi: 10.5812/hepatmon.7991. [PubMed: 23550108]
20. Jabbari H, Bayatian A, Sharifi AH, Zaer-Rezaee H, Fakharzadeh E, Asadi R, et al. Safety and efficacy of locally manufactured pegylated interferon in hepatitis C patients. Arch Iran Med. 2010;13(4):306–12. [PubMed: 20597564]
21. Jabbari H, Zamani F, Hatami K, Sheikholeslami A, Fakharzadeh E, Shahzamani K, et al. Pegaferon in hepatitis C: Results of a Multicenter Study. Middle East J Dig Dis. 2011;3(2):110–4. [PubMed: 25197541]
22. Namazee N, Sali S, Asadi S, Shafiei M, Behnava B, Alavian SM. Real response to therapy in chronic hepatitis C virus patients: a study from iran. Hepat Mon. 2012;12(9):e6151. doi: 10.5812/hepatmon.6151. [PubMed: 23087759]
23. Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis. Clin Infect Dis. 2013;56(7):961–7. doi: 10.1093/cid/cis1031. [PubMed: 23243171]
24. Rumi MG, Aghemo A, Prati GM, D'Ambrosio R, Donato MF, Soffredini R, et al. Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C. Gastroenterology. 2010;138(1):108–15. doi: 10.1053/j.gastro.2009.08.071. [PubMed: 19766645]